Monopar Therapeutics (NASDAQ:MNPR) Given "Buy" Rating at Chardan Capital

Key Points

• Monopar Therapeutics (NASDAQ:MNPR) received a "buy" rating from Chardan Capital, with a target price of $60.00, indicating a potential upside of 10.11% from its previous close.
• Multiple research firms, including BTIG and HC Wainwright, have also provided favorable ratings and higher price targets for the stock, leading to a consensus "buy" rating with an average target price of $71.75.
• The company's stock has shown significant volatility, with a 12-month trading range between $3.65 and $54.54, highlighting notable growth despite recent insider sales totaling over $1.7 million.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $60.00 target price on the stock. Chardan Capital's price target suggests a potential downside of 5.20% from the stock's previous close.

MNPR has been the topic of a number of other research reports. BTIG Research reissued a "buy" rating and issued a $87.00 price objective on shares of Monopar Therapeutics in a report on Monday, September 15th. HC Wainwright started coverage on shares of Monopar Therapeutics in a research report on Tuesday, August 26th. They issued a "buy" rating and a $70.00 price target on the stock. Oppenheimer initiated coverage on shares of Monopar Therapeutics in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $77.00 price objective for the company. Raymond James Financial initiated coverage on shares of Monopar Therapeutics in a research note on Tuesday, September 2nd. They set a "strong-buy" rating and a $80.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $74.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $71.75.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock traded down $2.96 during trading on Tuesday, hitting $63.29. The company's stock had a trading volume of 126,010 shares, compared to its average volume of 46,196. The company has a fifty day simple moving average of $41.66 and a two-hundred day simple moving average of $37.91. The company has a market capitalization of $390.50 million, a PE ratio of -19.01 and a beta of 1.20. Monopar Therapeutics has a 52 week low of $4.12 and a 52 week high of $68.18.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. As a group, analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Insiders Place Their Bets

In other news, Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $356,160.00. Following the transaction, the director owned 11,486 shares in the company, valued at $459,440. This represents a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the director owned 5,173 shares in the company, valued at approximately $206,920. This trade represents a 76.46% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,504 shares of company stock worth $1,700,160. 20.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics in the 2nd quarter worth approximately $34,000. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter valued at approximately $44,000. JPMorgan Chase & Co. lifted its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics in the 2nd quarter valued at $80,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Monopar Therapeutics during the 2nd quarter worth $104,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.